Literature DB >> 7495287

Diagnostic assessment of two novel proliferation-specific antigens in benign and malignant melanocytic lesions.

P Rudolph1, T Lappe, C Schubert, D Schmidt, R M Parwaresch, E Christophers.   

Abstract

The aim of this study was to gain a thorough insight into the proliferative activity of benign and malignant melanocytic tumors. A total of 314 cases were examined by immunohistochemistry on paraffin-embedded material. The growth fraction was assessed by means of two monoclonal antibodies, Ki-S1 and Ki-S5, which react with two different proliferation-specific nuclear antigens. Additionally, HMB-45 was used as a marker of melanocytic activation. Statistically significant differences (P < 0.01) in the proliferation rates were found between common acquired nevi, Spitz's/Reed's nevi, primary cutaneous melanomas, and metastatic melanomas, whereas dysplastic nevi were hardly distinct from other nevi of the compound type. In melanoma, the growth fraction correlated well with the tumor stage but poorly with HMB-45 expression and mitotic count. Along with tumor progression, an increasing heterogeneity of proliferation indices was observed. Our results provide no evidence for a progression from dysplastic nevi into melanoma. They indicate that the assessment of the proliferative activity may be of considerable diagnostic help in cases of uncertain histology and that it might contribute to an alternative concept for the classification of melanocytic tumors.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7495287      PMCID: PMC1869947     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  74 in total

1.  Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67.

Authors:  J Gerdes; L Li; C Schlueter; M Duchrow; C Wohlenberg; C Gerlach; I Stahmer; S Kloth; E Brandt; H D Flad
Journal:  Am J Pathol       Date:  1991-04       Impact factor: 4.307

2.  Antigen retrieval in formalin-fixed, paraffin-embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections.

Authors:  S R Shi; M E Key; K L Kalra
Journal:  J Histochem Cytochem       Date:  1991-06       Impact factor: 2.479

3.  DNA level, tumor thickness, and stereological estimates of nuclear volume in stage I cutaneous malignant melanomas. A comparative study with analysis of prognostic impact.

Authors:  F B Sørensen; I B Kristensen; F Grymer; A Jakobsen
Journal:  Am J Dermatopathol       Date:  1991-02       Impact factor: 1.533

4.  Stereological estimation of nuclear volume in benign and malignant melanocytic lesions of the skin. Inter- and intraobserver variability of malignancy grading.

Authors:  F B Sørensen; P D Ottosen
Journal:  Am J Dermatopathol       Date:  1991-04       Impact factor: 1.533

5.  Dysplastic melanocytic nevus. Immunohistochemical heterogeneity by melanosomal markers and S-100.

Authors:  T G Salopek; K Jimbow
Journal:  Am J Dermatopathol       Date:  1991-04       Impact factor: 1.533

6.  Multiparametric image cytometry of nevi and melanomas.

Authors:  M G Fleming; R J Friedman
Journal:  Am J Dermatopathol       Date:  1993-04       Impact factor: 1.533

7.  Validity of the histopathological criteria used for diagnosing dysplastic naevi. An interobserver study by the pathology subgroup of the EORTC Malignant Melanoma Cooperative Group.

Authors:  P E de Wit; B van't Hof-Grootenboer; D J Ruiter; R Bondi; E B Bröcker; J P Cesarini; N Hastrup; K Hou-Jensen; R M MacKie; E Scheffer
Journal:  Eur J Cancer       Date:  1993       Impact factor: 9.162

8.  Assignment of SV40-immortalized cells to more than one complementation group for immortalization.

Authors:  E L Duncan; N J Whitaker; E L Moy; R R Reddel
Journal:  Exp Cell Res       Date:  1993-04       Impact factor: 3.905

9.  Nevi, other than dysplastic and Spitz nevi.

Authors:  A J Cochran; C Bailly; E Paul; D Dolbeau
Journal:  Semin Diagn Pathol       Date:  1993-02       Impact factor: 3.464

10.  Ki-S1, a novel proliferative marker: flow cytometric assessment of staining in human breast carcinoma cells.

Authors:  R S Camplejohn; A Brock; D M Barnes; C Gillett; B Raikundalia; H Kreipe; M R Parwaresch
Journal:  Br J Cancer       Date:  1993-04       Impact factor: 7.640

View more
  8 in total

1.  Comparison of Ki-67 equivalent antibodies.

Authors:  C F Lindboe; S H Torp
Journal:  J Clin Pathol       Date:  2002-06       Impact factor: 3.411

2.  Prognostic relevance of a novel proliferation marker, Ki-S11, for soft-tissue sarcoma. A multivariate study.

Authors:  P Rudolph; U Kellner; A Chassevent; F Collin; F Bonichon; R Parwaresch; J M Coindre
Journal:  Am J Pathol       Date:  1997-06       Impact factor: 4.307

3.  Ki-A10, a germ cell nuclear antigen retained in a subset of germ cell-derived tumors.

Authors:  P Rudolph; U Kellner; D Schmidt; V Kirchner; A Talerman; D Harms; R Parwaresch
Journal:  Am J Pathol       Date:  1999-03       Impact factor: 4.307

4.  Prognostic significance of the proliferative activity in neuroblastoma.

Authors:  P Rudolph; T Lappe; B Hero; F Berthold; R Parwaresch; D Harms; D Schmidt
Journal:  Am J Pathol       Date:  1997-01       Impact factor: 4.307

5.  Telomerase activity in melanocytic lesions: A potential marker of tumor biology.

Authors:  P Rudolph; C Schubert; S Tamm; K Heidorn; A Hauschild; I Michalska; S Majewski; G Krupp; S Jablonska; R Parwaresch
Journal:  Am J Pathol       Date:  2000-04       Impact factor: 4.307

Review 6.  [The dysplastic nevus. Separate entity, melanoma precursor or diagnostic dilemma?].

Authors:  A Roesch; M Landthaler; T Vogt
Journal:  Hautarzt       Date:  2003-09       Impact factor: 0.751

Review 7.  Melanocytic nevi simulant of melanoma with medicolegal relevance.

Authors:  Guido Massi
Journal:  Virchows Arch       Date:  2007-07-26       Impact factor: 4.064

8.  Isolation and long-term expansion of murine epidermal stem-like cells.

Authors:  Jingjing Wang; Maureen Mongan; Xiang Zhang; Ying Xia
Journal:  PLoS One       Date:  2021-07-16       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.